Clinical characteristics of post-transplant lymphoproliferative disorders

Morrison, Vicki A.; Dünn, David L.; Manivel, J. Carlos; Gajl‐Peczalska, Kazimiera J.; Peterson, Bruce A.

doi:10.1016/0002-9343(94)90043-4

Cited by 222 publications

(131 citation statements)

References 35 publications

Supporting

Mentioning

122

Contrasting

Order By: Relevance

“…1, 2, 6, and 7) had sexmismatched grafts. 37,38 Unlike lymphomas that occur in immunocompetent patients, 11 extranodal involvement is common on presentation of PTLD. Localized hepatic PTLD, however, is uncommon.…”

Section: Ebv In Tumor Clonalitymentioning

confidence: 99%

“…7,10 The malignant lymphomas typically behave in a very aggressive fashion, with a far greater incidence of extranodal presentation and invasion of the central nervous system, a lesser likelihood of response to conventional lymphoma therapies, and poorer outcome than lymphomas in nontransplanted patients. 11 In light of these differences and the apparently greater incidence of PTLD in liver transplant recipients, we examined the clinical characteristics, course, and therapeutic outcome of PTLD in liver transplant recipients.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Posttransplantation lymphoproliferative disorder in liver recipients: Characteristics, management, and outcome

et al. 1999

View full text Add to dashboard Cite

Posttransplantation lymphoproliferative disorder (PTLD) is a well-recognized complication of organ transplantation. The aim of this study, performed over 9 years, was to examine the histopathological findings, clinical course, and outcome of patients who, having undergone orthotopic liver transplantation (OLT), developed PTLD. The sample included 7 adult liver allograft recipients (1.7%), 4 men and 3 women, with a mean age of 53 years (range, 40 to 61 years) who developed PTLD 1 to 36 months post-OLT (mean, 6 months). Four patients received either antithymocyte globulin as primary immunosuppression or OKT3 for steroidresistant cellular rejection. Four patients had localized hepatic tumor with or without regional lymph node involvement, 2 patients had extralymphoreticular disease (head of pancreas and chest wall), and 1 patient had spleen and lymph node involvement. All tumors were B-cell lymphomas; three polymorphic and four monomorphic. Clonality was assessed by immunostaining for kappa and lambda and gene rearrangement. Monoclonality was found in 4 patients and polyclonality in 2 (1 of whom progressed to monoclonality); in 2 patients, clonality could not be determined. Immunohistochemistry findings for the presence of the Epstein-Barr virus (EBV)-determined nuclear antigen and the latent membrane protein 1 were noted in lymphoma tissue in 6 patients. Immunosuppressive therapy was decreased in all patients. Polyclonal tumors were treated with acyclovir (1 patient is in complete remission and 1 patient died), and monoclonal tumors with systemic chemotherapy (2 patients are in complete remission and 2 patients died). One patient was treated with monoclonal antibodies (CD20) but failed to respond, and 1 patient was treated with excision and is in complete remission. The mortality rate was 43%; for the remainder, median survival is 21 months (range, 10 to 42 months). We conclude that PTLD may re-present early after OLT. EBV has a special role in the pathogenesis, combined with immunosuppressive therapy. The outcome is poor, and new therapeutic approaches are needed.

show abstract

Section: Ebv In Tumor Clonalitymentioning

confidence: 99%

mentioning

confidence: 99%

Posttransplantation lymphoproliferative disorder in liver recipients: Characteristics, management, and outcome

et al. 1999

View full text Add to dashboard Cite

show abstract

“…P osttransplant lymphoproliferative disorders (PTLDs), which usually represent expansion of B lymphocytes infected with Epstein-Barr virus (EBV), are a life-threatening complication of the immunosuppressive therapy necessary to prevent graft rejection (1,2). PTLDs comprise a whole spectrum of lymphoproliferative disorders ranging from a polyclonal atypical lymphoid hyperplasia to a monoclonal, overtly malignant B cell lymphoma (1)(2)(3)(4).…”

mentioning

confidence: 99%

“…PTLDs comprise a whole spectrum of lymphoproliferative disorders ranging from a polyclonal atypical lymphoid hyperplasia to a monoclonal, overtly malignant B cell lymphoma (1)(2)(3)(4). Less advanced forms of PTLDs respond to a decrease in the dose of the immunosuppressive agents (1,5). However, lowering the drug dose jeopardizes survival of the graft.…”

mentioning

confidence: 99%

The immunosuppressive macrolide RAD inhibits growth of human Epstein–Barr virus-transformed B lymphocytes in vitro and in vivo : A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders

Majewski

Korecka

Kossev

et al. 2000

Proc. Natl. Acad. Sci. U.S.A.

207

139

View full text Add to dashboard Cite

“…The patient had refused laparotomy, and bipedal lymphography was unsuccessful. Because the patient had some negative prognostic factors (i.e., male sex, age >60 years, histotype, and mass size >2.5 cm) and because of the likelihood that the Hodgkin's lymphoma had developed (and had persisted) during immunosuppression (poor prognosis for lymphomas during immunosuppression after transplantation [4]), he was treated with MOPP (mechlorethamine, vincristine, procarbazine, prednisone) and local radiotherapy.…”

mentioning

confidence: 99%

Epstein‐Barr virus‐associated Hodgkin's lymphoma in a rheumatoid arthritis patient treated with methotrexate and cyclosporin A

Ferraccioli

Casatta

Bartoli

et al. 1995

Arthritis & Rheumatism

View full text Add to dashboard Cite

Clinical characteristics of post-transplant lymphoproliferative disorders

Cited by 222 publications

References 35 publications

Posttransplantation lymphoproliferative disorder in liver recipients: Characteristics, management, and outcome

Posttransplantation lymphoproliferative disorder in liver recipients: Characteristics, management, and outcome

The immunosuppressive macrolide RAD inhibits growth of human Epstein–Barr virus-transformed B lymphocytes in vitro and in vivo : A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders

Epstein‐Barr virus‐associated Hodgkin's lymphoma in a rheumatoid arthritis patient treated with methotrexate and cyclosporin A

Contact Info

Product

Resources

About